Low-grade gliomas
Handbook of Clinical Neurology, ISSN: 0072-9752, Vol: 105, Page: 437-450
2012
- 11Citations
- 19Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations11
- Citation Indexes11
- CrossRef11
- 10
- Captures19
- Readers19
- 19
Book Chapter Description
Diffuse infiltrative low-grade gliomas of the cerebral hemispheres in the adult are a group of tumors with distinct clinical, histological, and molecular characteristics, and there are still controversies regarding management. The scientific evidence of papers collected from the literature was evaluated and graded according to European Federation of Neurological Societies guidelines, and recommendations were given accordingly. The World Health Organization classification recognizes grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas. Conventional magnetic resonance imaging is used for differential diagnosis, guiding surgery, planning radiotherapy, and monitoring treatment response. Advanced imaging techniques can increase the diagnostic accuracy. Younger age, normal neurological examination, oligodendroglial histology, and 1p loss are favorable prognostic factors. Prophylactic antiepileptic drugs are not useful, and there is no evidence that one drug is better than the others. Total/near-total resection can improve seizure control, progression-free and overall survival, while reducing the risk of malignant transformation. Early postoperative radiotherapy improves progression-free but not overall survival. Low doses of radiation are as effective as high doses, and better tolerated. Modern radiotherapy techniques reduce the risk of late cognitive deficits. Chemotherapy can be useful both at recurrence after radiotherapy and as initial treatment after surgery to delay the risk of late neurotoxicity from large-field radiotherapy. Neurocognitive deficits are frequent and can be caused by the tumor itself, tumor-related epilepsy, treatments, and psychological distress.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/B978044453502300001X; http://dx.doi.org/10.1016/b978-0-444-53502-3.00001-x; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84855529838&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/22230511; http://linkinghub.elsevier.com/retrieve/pii/B978044453502300001X; https://linkinghub.elsevier.com/retrieve/pii/B978044453502300001X
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know